Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PYC Therapeutics Limited ( (AU:PYC) ) has provided an update.
PYC Therapeutics Limited announced the cessation of certain securities due to unmet conditions, affecting options expiring in 2026, 2027, and 2028. This announcement may impact the company’s capital structure and investor relations, as it reflects on the company’s strategic decisions regarding its financial instruments.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited operates in the biotechnology industry, focusing on developing precision medicines. The company specializes in RNA therapeutics, targeting genetic disorders and diseases with unmet medical needs.
Average Trading Volume: 497,367
Technical Sentiment Signal: Buy
Current Market Cap: A$699.9M
For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.